Erasca (ERAS) Return on Capital Employed (2021 - 2026)
Erasca (ERAS) posted Return on Capital Employed of 72.93% for Q1 2026, down 96.55% on a QoQ basis from 37.1% in Q4 2025, and down 3470.0% year-over-year from 2.16% in Q1 2025.
Erasca (ERAS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Erasca's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 72.93% for Q1 2026.
- Quarterly Return on Capital Employed fell 3470.0% year-over-year to 72.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 72.93% (down 3470.0% YoY) and the FY2025 annual result came in at 33.48%, up 953.0% from the prior year.
- Return on Capital Employed was 72.93% for Q1 2026 at Erasca, down from 37.1% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.36% in Q1 2022 and bottomed at 72.93% in Q1 2026.
- A 5-year average of 43.36% and a median of 37.13% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 2519 bps — and 2026, when it plunged 3470 bps.
- Erasca's Return on Capital Employed stood at 57.28% in 2022, then jumped by 35 bps to 37.13% in 2023, then advanced by 0 bps to 37.08% in 2024, then decreased by 0 bps to 37.1% in 2025, then tumbled by 97 bps to 72.93% in 2026.
- Business Quant data shows ERAS's Return on Capital Employed at 72.93% in Q1 2026, 37.1% in Q4 2025, and 35.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | -72.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.93% |
| Dec 31, 2025 | -37.10% |
| Sep 30, 2025 | -35.63% |
| Jun 30, 2025 | -34.11% |
| Mar 31, 2025 | -38.22% |
| Dec 31, 2024 | -37.08% |
| Sep 30, 2024 | -35.74% |
| Jun 30, 2024 | -41.41% |
| Mar 31, 2024 | -40.68% |
| Dec 31, 2023 | -37.13% |
| Sep 30, 2023 | -60.93% |
| Jun 30, 2023 | -57.57% |
| Mar 31, 2023 | -53.25% |
| Dec 31, 2022 | -57.28% |
| Sep 30, 2022 | -33.60% |
| Jun 30, 2022 | -34.15% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -25.72% |
| Sep 30, 2021 | -46.40% |